RVL Pharmaceuticals plc
RVLPQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 5.64% | -2.37% | 184.10% | 171.13% | -11.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.64% | -2.37% | 184.10% | 171.13% | -11.14% |
| Cost of Revenue | 7.03% | 48.61% | 113.47% | 85.40% | 49.83% |
| Gross Profit | 5.35% | -9.36% | 199.42% | 200.59% | -18.19% |
| SG&A Expenses | -24.79% | -20.57% | -4.80% | 4.97% | 16.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.15% | -16.96% | -2.21% | 3.41% | 11.90% |
| Operating Income | 38.67% | 26.10% | 46.14% | 31.20% | -30.07% |
| Income Before Tax | -6.23% | 24.41% | 36.51% | 53.69% | 26.49% |
| Income Tax Expenses | -165.02% | -53.50% | -106.37% | 150.61% | 121.76% |
| Earnings from Continuing Operations | -5.11% | 24.50% | 36.78% | 53.42% | 24.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -100.33% | 267.80% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.81% | 9.09% | 20.38% | 46.94% | 37.80% |
| EBIT | 38.67% | 26.10% | 46.14% | 31.20% | -30.07% |
| EBITDA | 38.84% | 21.17% | 40.04% | 18.34% | -202.09% |
| EPS Basic | 7.48% | 32.48% | 41.16% | 60.75% | 47.96% |
| Normalized Basic EPS | 58.18% | 52.88% | 57.27% | 46.92% | -5.70% |
| EPS Diluted | 7.48% | 32.48% | 41.17% | 60.77% | 47.99% |
| Normalized Diluted EPS | 58.18% | 52.88% | 57.27% | 46.92% | -5.68% |
| Average Basic Shares Outstanding | 25.64% | 29.21% | 33.32% | 35.71% | 23.91% |
| Average Diluted Shares Outstanding | 25.64% | 29.21% | 33.32% | 35.71% | 23.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |